A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Avera McKennan Hospital & University Health Center
Institut Paoli-Calmettes
Mayo Clinic
Mayo Clinic
Duke University
University of Nebraska
Medical College of Wisconsin
Mayo Clinic
RenJi Hospital
West China Hospital
Cancer Research UK
NuCana plc
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comprehensive Support Project for Oncology Research
Sun Yat-sen University
Universitair Ziekenhuis Brussel
Massachusetts General Hospital
Western Sydney Local Health District
Guangzhou Women and Children's Medical Center
Hospices Civils de Lyon
Ciusss de L'Est de l'Île de Montréal
Abramson Cancer Center at Penn Medicine
Oncology Institute of Southern Switzerland
CureOne
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
University of Southern California
Rutgers, The State University of New Jersey
Chinese PLA General Hospital
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Roger Williams Medical Center
Netherlands Open University
University of New Mexico
SCRI Development Innovations, LLC